MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Authors: Fürstenau, Moritz ^{1, ∗}, Robrecht, Sandra ¹, Schneider, Christof ², Tausch, Eugen ², Giza, Adam ¹, Ritgen, Matthias ³, Bittenbring, Jörg ⁴, Hebart, Holger ⁵, Schöttker, Björn ⁶, Illert, Anna Lena ⁷, Graeven, Ullrich ⁸, Stoltefuß, Andrea ⁹, Heinrich, Bernhard ¹⁰, Eckert, Robert ¹¹, Fink, Anna ¹, Stumpf, Janina ¹, Fischer, Kirsten ¹, Al-Sawaf, Othman ¹, Simon, Florian ¹, Kleinert, Fanni ¹, Weiss, Jonathan ¹, Kreuzer, Karl-Anton ¹, Schilhabel, Anke ³, Brüggemann, Monika ³, Langerbeins, Petra ¹, Stilgenbauer, Stephan ², Eichhorst, Barbara ¹, Hallek, Michael ¹, Cramer, Paula ¹

Source: In Blood December 2024

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Authors: Fürstenau, Moritz, Giza, Adam, Weiss, Jonathan, Kleinert, Fanni, Robrecht, Sandra, Franzen, Fabian, Stumpf, Janina, Langerbeins, Petra, Al-Sawaf, Othman, Simon, Florian, Fink, Anna-Maria, Schneider, Christof, Tausch, Eugen, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Fischer, Kirsten, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula

Source: In Blood 18 July 2024 144(3):272-282

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

Authors: Cramer, Paula ^*, Fürstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Brüggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Source: In The Lancet Haematology October 2022 9(10):e745-e755

Next‐generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B‐cell precursor acute lymphoblastic leukaemia.

Authors: Bendig, Sonja, Bufe, Sandra, Kotrova, Michaela, Fricke, Birgit, Proske, Constantin, Darzentas, Franziska, Darzentas, Nikos, Schilhabel, Anke, Kehden, Britta, Chitadze, Guranda, Baldus, Claudia D., Gökbuget, Nicola, Brüggemann, Monika

Source: British Journal of Haematology; Jan2025, Vol. 206 Issue 1, p353-356, 4p

Subject Terms: LYMPHOBLASTIC leukemia, DNA, BLOOD plasma, MEASURING instruments, EARLY diagnosis, GLOBAL burden of disease, NUCLEOTIDE sequencing

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Authors: Fürstenau, Moritz, Fink, Anna Maria, Schilhabel, Anke, Weiss, Jonathan, Robrecht, Sandra, Eckert, Robert, de la Serna, Javier, Crespo, Marta, Coscia, Marta, Vitale, Candida, Böttcher, Sebastian, Weppner, Gesche, Ritgen, Matthias, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Brüggemann, Monika, Herling, Carmen D.

Source: Blood. 137(16):2267-2271

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183253063.0x000001&indx=1&recIds=ETOCvdc_100183253063.0x000001

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.

Authors: Schilhabel, Anke¹ (AUTHOR), Walter, Peter Jonas¹ (AUTHOR), Cramer, Paula² (AUTHOR), von Tresckow, Julia³ (AUTHOR), Kohlscheen, Saskia¹ (AUTHOR), Szczepanowski, Monika¹ (AUTHOR), Laqua, Anna¹ (AUTHOR), Fischer, Kirsten² (AUTHOR), Eichhorst, Barbara² (AUTHOR), Böttcher, Sebastian⁴ (AUTHOR), Schneider, Christof⁵ (AUTHOR), Tausch, Eugen⁵ (AUTHOR), Brüggemann, Monika¹ (AUTHOR), Kneba, Michael¹ (AUTHOR), Hallek, Michael² (AUTHOR), Ritgen, Matthias¹ (AUTHOR) matthias.ritgen@uksh.de

Source: Cancers. Oct2022, Vol. 14 Issue 19, p4917. 16p.

Subject Terms: *THERAPEUTIC use of monoclonal antibodies, *CHRONIC lymphocytic leukemia, *FLOW cytometry, *REFERENCE values, *CLINICAL trials, *ANTINEOPLASTIC agents, *RETROSPECTIVE studies, *GENE expression, *TUMOR markers, *CELL lines

The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category

Authors: Kotrova, Michaela, Fronkova, Eva, Svaton, Michael, Drandi, Daniela, Schön, Felix, Hoogeveen, Patricia, Hancock, Jeremy, Skotnicova, Aneta, Schilhabel, Anke, Eckert, Cornelia, Clappier, Emmanuelle, Cazzaniga, Gianni, Schäfer, Beat W., van Dongen, Jacques J. M., Ritgen, Matthias, Pott, Christiane, van der Velden, Vincent H. J., Trka, Jan, Brüggemann, Monika

Source: Leukemia; July 2024, Vol. 38 Issue: 7 p1617-1620, 4p

Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia.

Authors: Schilhabel, Anke, Szczepanowski, Monika, van Gastel-Mol, Ellen J., Schillalies, Janina, Ray, Jill, Kim, Doris, Nováková, Michaela, Dombrink, Isabel, van der Velden, Vincent H. J., Boettcher, Sebastian, Brüggemann, Monika, Kneba, Michael, van Dongen, Jacques J. M., Langerak, Anton W., Ritgen, Matthias

Source: Frontiers in Oncology; 1/16/2023, Vol. 13, p01-10, 10p

Subject Terms: LYMPHOCYTIC leukemia, NUCLEOTIDE sequencing, INDIVIDUALIZED medicine, HEMATOLOGIC malignancies, DETECTION limit

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Authors: Furstenau, Moritz, Giza, Adam, Fink, Anna-Maria, Robrecht, Sandra, Weiss, Jonathan, Kleinert, Fanni, Schneider, Christof, Tausch, Eugen, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara F., Hallek, Michael, Cramer, Paula

Source: In Blood 2 November 2023 142 Supplement 1:203-203

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Authors: Furstenau, Moritz, Giza, Adam, Schneider, Christof, Tausch, Eugen, Robrecht, Sandra, Ritgen, Matthias, Bittenbring, Jörg, Hebart, Holger F., Schöttker, Björn, Illert, Anna Lena, Graeven, Ullrich, Stoltefuss, Andrea, Heinrich, Bernhard, Eckert, Robert, Fink, Anna-Maria, Stumpf, Janina, Simon, Florian, Fischer, Kirsten, Al-Sawaf, Othman, Langerbeins, Petra, Kleinert, Fanni, Weiss, Jonathan, Kreuzer, Karl-Anton, Schilhabel, Anke, Brüggemann, Monika, Eichhorst, Barbara F., Stilgenbauer, Stephan, Hallek, Michael, Cramer, Paula

Source: In Blood 2 November 2023 142 Supplement 1:1897-1897

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Authors: Fürstenau, Moritz, Ritgen, Matthias, Robrecht, Sandra, Von Tresckow, Julia, Zhang, Can, Schilhabel, Anke, Gregor, Michael, Thornton, Patrick, Staber, Philipp Bernhard, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf A., Heintel, Daniel, Poulsen, Christian Bjørn, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus, Issa, Djamila, Visser, Hein, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Voehringer, Matthias C., Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily, Kreuzer, Karl-Anton, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Kater, Arnon P., Niemann, Carsten Utoft, Eichhorst, Barbara F.

Source: In Blood 2 November 2023 142 Supplement 1:635-635

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME‐LIMITED TREATMENT WITH ANTI‐CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2‐BAG, ‐BCG, ‐BIG AND ‐BIO PHASE‐II TRIALS.

Authors: Yosifov, Deyan, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Jebaraj, Billy, Mertens, Daniel, Ritgen, Matthias, Schilhabel, Anke, Kreuzer, Karl‐Anton, Maria Fink, Anna, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Cramer, Paula, Tausch, Eugen

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-3, 3p

The Ether-Cleaving Methyltransferase System of the Strict Anaerobe Acetobacterium dehalogenans: Analysis and Expression of the Encoding Genes.

Authors: Schilhabel, Anke, Studenik, Sandra, Vödisch, Martin

Source: Journal of Bacteriology; January 2009, Vol. 191 Issue 2, p588-599, 12p

Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL

Authors: Khouja, Mouhamad, Schilhabel, Anke, Kotrova, Michaela, Brüggemann, Monika, Kuffer, Christian, Blair, Derek, Darzentas, Nikos, Pott, Christiane

Source: In Blood 23 November 2021 138 Supplement 1:3498-3498

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Authors: Fürstenau, Moritz, Schilhabel, Anke, Robrecht, Sandra, Zhang, Can, Von Tresckow, Julia, Niemann, Carsten Utoft, Kater, Arnon P., Tausch, Eugen, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Van Oers, Marinus H.J., Da Cunha-Bang, Caspar, Geisler, Christian H., Stilgenbauer, Stephan, Brüggemann, Monika, Hallek, Michael, Ritgen, Matthias, Eichhorst, Barbara

Source: In Blood 23 November 2021 138 Supplement 1:72-72

P829: GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA.

Authors: Schilhabel, Anke, Khouja, Mouhamad, Stewart, Peter, Strifler, Susanne, Stuebig, Thomas, Kull, Miriam, Baldus, Claudia, Pott, Christiane, Gonzalez de Castro, David, Engelhardt, Monika, Krönke, Jan, Einsele, Hermann, Knop, Stefan, Brüggemann, Monika

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p

This result is not displayed to guests.
Login for full access.

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Authors: Fischer, Kirsten ^*, Ritgen, Matthias ^*, Al-Sawaf, Othman ^*, Robrecht, Sandra ^*, Tandon, Maneesh ^*, Fink, Anna-Maria ^*, Schilhabel, Anke ^*, Stübig, Thomas ^*, Brüggemann, Monika ^*, Jiang, Yanwen ^*, Schary, William, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Tausch, Eugen ^*, Kreuzer, Karl-Anton ^*, Langerak, Anton W ^*, Goede, Valentin ^*, Böttcher, Sebastian ^*, Stilgenbauer, Stephan, Kneba, Michael ^*, Hallek, Michael

Source: In Blood 13 November 2019 134 Supplement 1:36-36

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.